Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer

Pathology Research and Practice

Volumn 209, Issue 6, 2013, Pages 345-352

  Xu, Xiao Yan ^a   Lin, Ni ^a   Li, Yu Mei ^a   Zhi, Cheng ^a   Shen, Hong ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

HAb18G CD147; Localization; Non small cell lung cancer; Progression and prognosis; Survival

Indexed keywords

CD147 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HAB18G; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; TUMOR CELL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD147; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84878399155     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2013.02.015     Document Type: Article

References (36)

1. Carney D.N. Lung cancer-time to move on from chemotherapy. N. Engl. J. Med. 2002, 346:126-128.
2. Z.N. Chen, P. Shang, Y. Li, et al., NTD Patent & Trademark Agency Ltd., Beijing office, assignee. HAb18G/CD147, its agonist and application. Chinese patent ZL01131735.3, September 28 2001; PCT international patent WO02/094875.27 May 2002.
3. Suzuki S., Sato M., Senoo H., Ishikawa K. Direct cell-cell interaction enhances pro-MMP-2 production and activation in co-culture of laryngeal cancer cells and fibroblasts: involvement of EMMPRIN and MT1-MMP. Exp. Cell Res. 2004, 293:259-266.
4. Rucci N., Millimaggi D., Mari M., et al. Receptor activator of NF-κB Ligand Enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/cd147. Cancer Res. 2010, 70:6150-6160.
5. Li Y., Xu J., Chen L., Zhong W.D., et al. HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology 2009, 54:677-687.
6. Xu J., Xu H.Y., Zhang Q., et al. HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol. Cancer Res. 2007, 5:605-614.
7. Yu X.L., Hu T., Du J.M., et al. Crystal structure of HAb18G/CD147: implications for immunoglobulin superfamily homophilic adhesion. J. Biol. Chem. 2008, 283:18056-18065.
8. Liu F.F., Cui L.F., Zhang Y., et al. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Breast Cancer Res. Treat. 2010, 124:677-688.
9. Zhong W.D., Liang Y.X., Lin S.X., et al. Expression of CD147 is associated with prostate cancer progression. Int. J. Cancer 2012, 130:300-308.
10. Frank C., Detterbeck M.D., et al. The new lung cancer staging system. Chest 2009, 136:260-271.
11. Travis W.D., Brambilla E., Noguchi M., et al. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. J. Thorac. Oncol. 2011, 6:244-285.
12. Bai X.Y., Shen H. Mutational analysis of thyroid transcription factor-1 gene (TTF-1) in lung carcinomas. In Vitro Cell. Dev. Biol. Anim. 2008, 44:17-25.
13. Xue Y.J., Lu Q., Sun Z.X. CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer. Med. Oncol. 2010, 28:1363-1372.
14. Caudroy S., Polette M., Tournier J.M., et al. Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J. Histochem. Cytochem. 1999, 47:1575-1580.
15. Jin J.S., Yao C.W., Loh Shih hurng, et al. Increasing expression of extracellular matrix Metalloproteinase inducer in ovary tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int. J. Gynecol. Pathol. 2006, 25:140-146.
16. Zheng H.C., Takahashi H., Murai Y., et al. Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastriccarcinoma:a good marker for local invasion and prognosis. Br. J. Cancer 2006, 95:1371-1378.
17. Tan H., Ye K., Wang Z., et al. CD147 expression as a significant prognostic factor in differentiated thyroid carcinoma. Transl. Res. 2008, 152:143-149.
18. Liu A.G., Hu Q., Liu S.Y., et al. The expressions of CD147 and MMP-9 in non-Hodgkin's lymphoma cells and the relation to prognosis. Chin. Ger. J. Clin. Oncol. 2009, 8:705-708.
19. Wulf S., Bernhard P., Karimah E., et al. Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9. Mod. Pathol. 2008, 21:1130-1138.
20. Yoshizawa A., Motoi N., Riely G.J., et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod. Pathol. 2011, 6:1496-1504.
21. Russell P.A., Wainer Z., Wright G.M., et al. Does lung adenocarcinoma subtype predict patient survival: a clinicopathologic study based on the new international association for study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification. J. Thorac. Oncol. 2007, 2:706-714.
22. Kirk P., Wilson M.C., Heddle C., et al. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J. 2000, 19:3896-3904.
23. Xu D., Hemler M.E. Metabolic activation-related CD147-CD98 complex. Mol. Cell. Proteomics 2005, 4:1061-1071.
24. Berditchevski F., Chang S., Bodorova J., et al. Generation of monoclonal antibodies to integrin-associated proteins. Evidence that alpha3beta1complexes with EMMPRIN/basigin/OX47/M6. J. Biol. Chem. 1997, 272:29174-29180.
25. Curtin K.D., Meinertzhagen I.A., Wyman R.J. Basigin (EMMPRIN/CD147) interacts with integrin to affect cellular architecture. J. Cell Sci. 2005, 118:2649-2660.
26. Yan L., Zucker S., Toole B.P., et al. Roles of the multifunctional glycoprotein, emmprin (basigin;CD147), in tumour progression. Thromb. Haemost. 2005, 93:199-204.
27. Tang Y., Kesavan P., Nakada M.T., Yan L. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol. Cancer Res. 2004, 2:73-80.
28. Moll U.M., Lane B., Zucker S., Suzuki K., Nagase H. Localization of collagenase at the basal plasma membrane of a human pancreatic carcinoma cell line. Cancer Res. 1990, 50:6995-7002.
29. Caudroy S., PoletteM, Nawrocki-Raby B., et al. EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin. Exp. Metastasis 2002, 19:697-702.
30. Menashi S., Serova M., Ma L., Vignot S., Mourah S., Calvo F. Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer Res. 2003, 63:7575-7580.
31. Zucker S., Hymowitz M., Rollo E.E., et al. Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am. J. Pathol. 2001, 158:1921-1928.
32. Betsuyaku T., Tanino M., Nagai K., et al. Extracellular matrix metalloproteinase inducer is increased in smokers' bronchoalveolar lavage fluid. Am. J. Respir. Crit. Care Med. 2003, 168:222-227.
33. Zhu S., Li Y., Mi L., et al. Clinical impact of HAb18G/CD147 expression in esophageal squamous cell carcinoma. Dig. Dis. Sci. 2011, 56:3569-3576.
34. Hakuma N., Betsuyaku T., Kinoshita I., et al. High incidence of extracellular matrix metalloproteinase inducer expression in non-small cell lung cancers. Association with clinicopathological parameters. Oncology 2007, 72:197-204.
35. Wang S.J., Tang J., Zhao P., et al. HAb18G/CD147 promotes cell motility by regulating annexin II-activated RhoA and Rac1 signaling pathways in HCC cells. Hepatology 2011, 54:2012-2014.
36. Wolf K., Mazo I., Leung H., et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell. Biol. 2003, 160:267-277.